Ainos (NASDAQ:AIMD – Get Free Report) and Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.
Insider & Institutional Ownership
75.9% of Nektar Therapeutics shares are held by institutional investors. 9.8% of Ainos shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Ainos has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ainos | $18,111.00 | 800.11 | -$14.77 million | ($2.89) | -0.59 |
| Nektar Therapeutics | $55.23 million | 43.21 | -$164.08 million | ($8.42) | -8.39 |
Ainos has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for Ainos and Nektar Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ainos | 1 | 0 | 0 | 0 | 1.00 |
| Nektar Therapeutics | 1 | 1 | 9 | 0 | 2.73 |
Nektar Therapeutics has a consensus target price of $149.63, indicating a potential upside of 111.87%. Given Nektar Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Ainos.
Profitability
This table compares Ainos and Nektar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ainos | -11,912.10% | -160.55% | -62.29% |
| Nektar Therapeutics | -284.18% | -85.40% | -39.99% |
Summary
Nektar Therapeutics beats Ainos on 8 of the 14 factors compared between the two stocks.
About Ainos
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Receive News & Ratings for Ainos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ainos and related companies with MarketBeat.com's FREE daily email newsletter.
